Phase 3 Prostate Cancer Trial, Recruiting NCT06350825 Sponsor: The First Affiliated Hospital with Nanjing Medical University Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT06350825
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men aged 18 to 75 years old
  • People whose prostate cancer has been confirmed by a tissue biopsy to be a specific type called adenocarcinoma
  • People whose cancer has spread (metastasised) to other parts of the body, confirmed by imaging scans or biopsy
  • People whose cancer has spread to distant lymph nodes, bones, or internal organs
  • People whose prostate cancer has not previously been treated with local treatments such as radiation therapy or cryotherapy to the prostate
  • People whose surgeon considers the prostate to be removable by surgery

Who may not be able to join:

  • People whose surgeon considers the cancer cannot be surgically removed
  • People whose life expectancy is estimated to be less than 2 years
  • People who currently have active spinal cord compression
  • People who have previously had local treatment for prostate cancer
  • People who have difficulty swallowing, ongoing diarrhea, a bowel obstruction, or other conditions that may affect the ability to take or absorb medication
  • People who are unwilling to sign the required consent forms
  • People whom the trial investigator considers unsuitable for the trial for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lixin Hua, M.D., The First Affiliated Hospital with Nanjing Medical University

Phone: 13072564303

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 January 2016
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

rPFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov